Best Pathway To Interchangeable Insulins Is In The Eye Of The Beholder
Executive Summary
Approaches suggested at a US FDA public hearing include allowing follow-on insulins to take a direct route to interchangeability without first having to be approved as biosimilars, and automatically declaring biosimilar insulins interchangeable with one or more reference products.
You may also be interested in...
FDA Publishes Immunogenicity Guidelines For Biosimilar Insulins
In a move that will likely be welcomed by industry, the US FDA has issued draft guidance stating that sponsors will generally not need to conduct comparative clinical immunogenicity studies in developing biosimilar/interchangeable products.
Biosimilar Insulins (Generally) Won't Need Comparative Clinical Immunogenicity Data, US FDA Says
In a move that will likely be welcomed by industry, the US FDA issued draft guidance stating that sponsors will generally not need to conduct comparative clinical immunogenicity studies in developing biosimilar/interchangeable products.
US FDA Will Allow Transitioning Products To Continue Referencing Drug Master Files
The 'technical detail' needed to be resolved in part to ensure there would be no shortages after the 2020 change from regulation as drugs to biologics for certain protein products, the agency said.